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ABSTRACT 149 
Topic: Our objective was to estimate the prevalence of non-refractive visual impairment and 150 
blindness in European subjects aged 55 years and older. 151 
Clinical relevance: Few visual impairment and blindness prevalence estimates are available for the 152 
European population. In addition, many of the data collected in European population-based studies 153 
are currently unpublished and have not been included in previous estimates. 154 
Methods: Fourteen European population-based studies participating in the European Eye 155 
Epidemiology (E3) consortium (N=70,723) were included. Each study provided non-refractive visual 156 
impairment and blindness prevalence estimates stratified by age (10 years strata) and gender. Non-157 
refractive visual impairment and blindness were defined as best-corrected visual acuity (BCVA) worse 158 
than 20/60 and 20/400 in the better eye, respectively. Using random effects meta-analysis, 159 
prevalence rates were estimated according to age, gender, geographical area and time period (1991-160 
2006; 2007-2012). Since no data were available for Central and Eastern Europe, population 161 
projections for numbers of affected people were estimated using Eurostat population estimates for 162 
European high-income countries in 2000 and 2010. 163 
Results: The age-standardized prevalence of non-refractive visual impairment in people aged 55 164 
years or older decreased from 2.22% (95% confidence interval (CI): 1.34-3.10) in 1991-2006, to 0.83% 165 
(95% CI: 0.38-1.28) in 2007-2012. It strongly increased with age in both time periods (up to 15.69 % 166 
and 4.39% in subjects aged 85 or more in 1991-2006 and 2007-2012, respectively). Age-standardized 167 
prevalence of visual impairment tended to be higher in women than men in 1991-2006 (2.67% versus 168 
1.88%), but not in 2007-2012 (0.87% versus 0.88%). No differences were observed between 169 
Northern, Western and Southern regions of Europe. The projected numbers of affected older 170 
inhabitants in European high-income countries decreased from 2.5 million affected subjects in 2000 171 
to 1.2 million in 2010. Of those, 584,000 were blind in 2000, by comparison with 170,000 in 2010.  172 
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Conclusions: Despite the increase in the European older population, our study indicates that the 173 
number of visually impaired people has decreased in European high-income countries in the last 174 
twenty years. This may be due to major improvements in eye care and prevention and/or decreasing 175 
prevalence of eye diseases.  176 
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Visual impairment and blindness have profound human and socioeconomic consequences in all 177 
societies. People with vision loss experience a reduced quality of life,1, 2 greater difficulty with daily 178 
living and social dependence,3, 4 higher rates of depression 5, 6 and an increased risk of falls and 179 
related hip fractures.7, 8 Worldwide, vision loss is a leading cause of disability. 9 The costs of lost 180 
productivity, rehabilitation, and education of the blind constitute a considerable economic burden for 181 
the individuals, their family, and society. Vision loss also incurs both direct health care costs and 182 
indirect costs of lost productivity, welfare, and informal care10. The global annual cost of visual 183 
impairment was estimated to be 3000 billion US dollars (563 billion US dollars for Europe).11 Since 184 
1999, prevention of visual impairment and blindness has been a priority of the World Health 185 
Organization (WHO), through its joint program with the International Agency for the Prevention of 186 
Blindness, known as “VISION2020 –the Right to Sight”.12 In 2013, the World Health Assembly adopted 187 
a new global action plan for the prevention of avoidable blindness and visual impairment for the period 188 
2014–2019.13 189 
A common cause of visual impairment is refractive error (such as myopia, hyperopia, astigmatism or 190 
presbyopia), which can be corrected using optical correction (spectacles or contact lenses).14 Thus, 191 
visual impairment due to refractive error is often termed “correctable visual impairment”, while visual 192 
impairment from other causes is often termed “uncorrectable visual impairment” or “non-refractive 193 
visual impairment”.  Worldwide, major causes of non-refractive visual impairment currently are age-194 
related eye diseases (cataract, age-related macular degeneration (AMD), glaucoma, and diabetic 195 
retinopathy).15 For this reason, visual impairment is much more frequent in older individuals. Globally, 196 
65% of visually impaired and 82% of the blind subject are aged 50 years or more.15 197 
  198 
While estimates of the prevalence of visual impairment and blindness are regularly published for the 199 
USA,16-19 such estimates are less reported for the European population. Although many 200 
epidemiological studies have been conducted in Europe,2, 20-24 there have been few attempts to 201 
harmonize these studies in order to provide estimations of the prevalence of visual impairment 202 
throughout the continent. In 2011, the EUREYE study suggested that the prevalence of visual 203 
impairment and blindness may be higher in Southern Europe than in Northern Europe (with the 204 
exception of Tallinn, Estonia, demonstrating prevalence rates as high as in Southern Europe) and that 205 
European women may be more affected than European men.2 However, this study was performed in 6 206 
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cities from 6 European countries (Bergen, Norway; Tallinn, Estonia; Belfast, UK; Paris-Créteil, France; 207 
Verona, Italy; Thessaloniki, Greece), with a total of 4166 participants, and may not be representative 208 
of the whole European continent. In 2014, prevalence rates for the European continent were estimated 209 
in a systematic review and meta-analysis performed by the expert group convened for the Global 210 
Burden of Diseases, Injuries and Risk Factors (GBD).25, 26 This meta-analysis suggests that the 211 
prevalence of visual impairment and blindness has decreased in recent decades in all continents, and 212 
in particular in Europe. It also showed higher prevalence rates of visual impairment in Central and 213 
Eastern Europe compared with Western Europe, and somewhat higher prevalence of visual 214 
impairment in women compared with men. However, because this meta-analysis relied on published 215 
data, the definitions (thresholds, type of optical correction) and reporting (in particular age groups) of 216 
visual impairment differed widely among the included studies, although these differences were in part 217 
addressed by the authors using complex statistical modeling. In addition, many European population-218 
based studies have collected data on visual impairment without publishing prevalence estimates, and 219 
thus could not be included in this meta-analysis. 220 
The European Eye Epidemiology (E3) consortium is a collaborative initiative between 41 221 
epidemiological studies across Europe to share and meta-analyze epidemiological data on ocular 222 
health.27 The aim of the present study was to provide more precise estimates of the prevalence of non-223 
refractive visual impairment in older Europeans and to assess potential temporal trends and 224 
geographical variations. 225 
 226 
POPULATIONS AND METHODS 227 
Studies and participants 228 
To date, E3 comprises data from 41 studies with a range of ophthalmic data on approximately 170,000 229 
individuals from population-based and other studies (case-control, cases only, randomized trials).27  230 
The present study was based on the fourteen E3 population-based studies that collected best-231 
corrected visual acuity (BCVA) data (n=70,723). Studies in the E3 consortium were eligible for 232 
inclusion in this analysis if they were population-based, and had available data on BCVA, together with 233 
sex, age at measurement, and year of measurement.  234 
10 
 
As described in Table 1, participants included in this meta-analysis were mainly of middle to late age. 235 
Because only few studies included subjects younger than 55 years, we estimated prevalence of visual 236 
impairment and blindness only in subjects above this age. Visual acuity measurements were 237 
performed between 1991 and 2012. Designs and methods of included studies are described in 238 
Supplementary Online material (available at aaojournal.org). All studies adhered to the tenets of the 239 
Declaration of Helsinki, and relevant local ethical committee approvals with specific study consent 240 
were obtained. 241 
 242 
Demographic and outcome variables  243 
All included studies measured distance visual acuity (mostly using Snellen or Early Treatment of 244 
Diabetic Retinopathy Study (ETDRS) charts), with optimal refractive correction. Definitions of visual 245 
impairment and blindness vary in the literature. According to the WHO, moderate to severe visual 246 
impairment is defined as a visual acuity in the better eye <6/18 but ≥3/60 while blindness is defined as 247 
a visual acuity <3/60. By contrast, in the United States, the threshold for visual impairment is 20/40. In 248 
order to be as comparable as possible with previous studies and use all available data in the 249 
participating studies, we used the following definitions of visual impairment and blindness: 250 
- Non-refractive visual impairment (WHO standard): BCVA<6/18 (or 20/60) in better eye 251 
- Non-refractive visual impairment (US standard): BCVA<6/12 (or 20/40) in better eye 252 
- Non-refractive blindness: BCVA<3/60 (or 20/400) in better eye 253 
Differences in visual impairment by age (in ten year age bands from 55-64 years to ≥85 years), sex, 254 
time period (1991-2006 and 2007-2012, using the median of study periods), and geographical 255 
European region were examined. Countries were divided into three regions (Northern, Western, and 256 
Southern Europe) according to the United Nations Geoscheme 28. No data were available from 257 
Eastern Europe. 258 
 259 
 260 
 261 
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Statistical analysis 262 
For each visual endpoint, the investigators from each study provided the number of individuals 263 
stratified by sex and age group (55-64 years, 65-74 years, 75-84 years, 85 years or older). Random 264 
effects meta-analyses were performed to estimate prevalence rates. Random effects modeling was 265 
chosen over a fixed effects model, to take into account heterogeneity in study design characteristics. 266 
Subgroups with less than 50 observations were excluded from the analyses. 267 
We first evaluated the variation in prevalence of non-refractive visual impairment and blindness with 268 
sex, time period, and geographical area. Since non-refractive visual impairment and blindness strongly 269 
vary with age and the age range was quite different among studies, we estimated age-standardized 270 
prevalence rates for all aged ≥ 55 years, using the following steps: firstly, for each stratum of sex, 271 
period, and geographical area, prevalence rates were estimated using random-effect meta-analyses in 272 
each age group (55-64 years, 65-74 years, 75-84 years, 85 years or older). Secondly, an age-273 
standardization to age-specific European population was performed using the European Standard 274 
Population 2010 29. This enabled prevalence estimates that are representative for the European 275 
population, with appropriate weighting to the age demographic distribution of Europe. Subsequently, 276 
random effects meta-analyses were performed with stratification by age, sex and time-period.  277 
Finally, in order to estimate the numbers of people affected by visual impairment and blindness, we 278 
applied the age- and period-specific prevalence rates to the population of European high-income 279 
countries, as defined by the GBD (Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, 280 
Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Spain, 281 
Sweden, Switzerland, United Kingdom).25 Population estimates were obtained from Eurostat. To 282 
obtain the estimates of numbers of people affected by visual impairment and blindness for the year 283 
2000, we applied prevalence estimates of visual impairment and blindness for the 1991-2006 period to 284 
the Eurostat estimates of population for year 2000. Similarly, for the year 2010, we applied visual 285 
impairment and blindness prevalence estimates for the 2007-2012 period to the Eurostat population 286 
estimates for year 2010. 287 
Statistical analysis was performed using R (R Development Core Team (2013). R: A language and 288 
environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria).  289 
 290 
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RESULTS 291 
Fourteen studies were included in the statistical analysis (Table 1). They were conducted between 292 
1991 and 2012 and included 70,723 participants. Age-specific prevalence estimates of the different 293 
visual endpoints in the participating studies are presented in Figure 1. The prevalence of non-294 
refractive visual impairment strongly increased with age in all studies. For non-refractive blindness, 295 
increasing prevalence with age was not so obvious in some studies, but this was mainly due to low 296 
number of affected subjects, particularly in the older age groups. A significant inter-study variability in 297 
age-specific prevalence estimates was observed, again especially in the older age groups.  298 
In Table 2, we estimated age-standardized prevalence rates of visual endpoints according to several 299 
factors (sex, period of eye examination, and geographical area). Prevalence of all visual endpoints 300 
tended to be somewhat higher in women, but the confidence intervals were largely overlapping with 301 
those of men. Age-standardized prevalence rates of all visual endpoints were much lower in the most 302 
recent time period (2007-2012) in comparison to the older studies (1991-2006). Indeed, the 303 
prevalence of non-refractive visual impairment (WHO standard) decreased from 2.22% to 0.83% 304 
(p=0.02). As shown in Figure 2, the differences were more pronounced in the older participants, and 305 
particularly striking in individuals aged 85 years or more: prevalence of non-refractive visual 306 
impairment (WHO standard) was 15.69 % before 2006 and less than 4.39% after 2006. Similarly, in 307 
this age group, prevalence of non-refractive blindness was about 3.26% before 2006 and 0.82% after 308 
2006. By contrast, we observed no clear difference of prevalence of visual impairment and blindness 309 
between Northern, Western and Southern Europe (for instance, for non-refractive visual impairment 310 
1.64 %, 1.55 % and 1.53 %, respectively, p=0.40). 311 
In Table 3, we estimated the prevalence rates and their 95% confidence intervals, for each age- and 312 
sex-strata in 1991-2006 and in 2007-2012. Women showed higher prevalence rates of all visual 313 
endpoints in studies performed before 2006, in particular in the oldest-old (for instance, for non-314 
refractive visual impairment, 21.45 % versus 13.11% in men, p=0.08). However, the difference was 315 
less pronounced in the more recent studies, with very similar prevalence rates in men and women in 316 
most age categories (for instance, for non-refractive visual impairment in the 85+ age category, 3.93% 317 
versus 4.03% in men, p=0.40).  318 
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In Table 4, we estimated the total number of inhabitants of European high income countries, affected 319 
by non-refractive visual impairment and blindness, in 2000 and 2010. Although the total number of 320 
subjects aged 55 years or more increased from 106 million in 2000 to 123 million in 2010, the number 321 
of subjects affected by non-refractive visual impairment decreased from 2.5 million to 1.2 million (5.2 322 
million to 3.8 million when using the US standard). Similar decreases were observed for non-refractive 323 
blindness (584,000 to 170,000). 324 
 325 
DISCUSSION 326 
This study, which summarizes published and unpublished data from 14 studies performed in Europe 327 
from 1991 to 2012, provides evidence for a major decrease in the prevalence of non-refractive visual 328 
impairment and blindness in older Europeans in recent years. The age-standardized prevalence of 329 
non-refractive visual impairment in people aged 55 years or older decreased from 2.22% in 1991-330 
2006, to 0.83% in 2007-2012. It tended to be higher in women than men in 1991-2006 (2.67% versus 331 
1.88%), but not in 2007-2012 (0.87% versus 0.88%). No differences were observed according to 332 
geographical area. The projected numbers of affected older inhabitants in European high-income 333 
countries decreased from 2.5 million affected subjects in 2000 to 1.2 million in 2010.  334 
In a meta-analysis of population-based studies from high-income countries (including United States, 335 
Australia, and Europe) performed in the 1990’s, the prevalence rates for non-refractive visual 336 
impairment according to US standards (BCVA<20/40) were very similar to our estimates, varying 337 
from 0.56% in subjects aged 55 to 59 years to 23.73 % in subjects 80 years or older16 (in comparison 338 
with 0.72 % in subjects aged 55-64 years to 28.95% in those age 85 years or more for the 1991-2006 339 
period in the present study). In the National Health and Nutrition Examination Study (NHANES), the 340 
prevalence of non-refractive visual impairment (BCVA<20/40) in non-Hispanic whites aged 60 years 341 
or more was 3.9% (95% CI: 3.3 %-4.6 %) in 1999-2002, increasing to 4.5 % (95 % CI: 3.6%-5.3 %) in 342 
2006-2008.19 We observed a similar estimate in 1991-2006  (4.68 %, 95 % CI:2.68%-6.68%) for the 343 
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period 1991-2006, with largely overlapping confidence intervals,  but a lower estimate in 2007-2012 344 
(2.86%, 95% CI: 1.52%-4.20%).19 This difference might be due to different temporal trends in Europe 345 
and the United States (with stability or even increase in the United States, contrasting with decrease 346 
in Europe) or to the fact that the decrease in prevalence of non-refractive visual impairment has 347 
happened after 2008, and thus was not observed in NHANES. To our knowledge, there are no 348 
available estimates of the prevalence of visual impairment in the United States after 2008. However, 349 
the GBD meta-analysis is also in favor of a decreasing prevalence of visual impairment in Northern 350 
America (from 3.5% in 1990 to 2.5% in 2010 for presenting visual acuity (PVA)<20/60).26 351 
The results of the GBD meta-analysis are not directly comparable to the present study, since they 352 
were based on presenting visual acuity (PVA), thus including visual impairment due to refractive 353 
errors. However, the temporal trends were similar to our study. Indeed, in the GBD study, the 354 
prevalence of visual impairment and blindness (PVA<20/60 and PVA<20/400, respectively) decreased 355 
worldwide from 1990 to 2010.25 This was in particular the case in European high-income countries, 356 
with a prevalence of visual impairment in subjects aged 50 years or more estimated at 6.2% (95% 357 
confidence interval (CI): 4.3%- 9.5%) in 1990 and 3.9% (95% CI: 2.8%- 6.6%) in 2010.26 Since they 358 
estimated that 47% of visual impairment was due to refractive errors at both time points, their 359 
estimates appear somewhat higher than ours (2.22% and 0.83% for non-refractive visual impairment 360 
and blindness, respectively). 361 
In the present study, the prevalence of non-refractive visual impairment was also halved in the most 362 
recent period (2.22% in 1991-2006 compared with 0.83% in 2007-2012). This suggests that visual 363 
impairment due to eye diseases has decreased with time. Unfortunately, causes of visual impairment 364 
and blindness were available only in some of the included studies, mainly because of incomplete eye 365 
examinations in many studies (in particular absence of assessment of lens opacities, impeding the 366 
diagnosis of cataract, and absence of visual field testing, impeding the diagnosis of glaucoma, which 367 
are leading causes of visual impairment). The decrease in non-refractive visual impairment is most 368 
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probably due to improvement in ophthalmological care over the last 20 years, with an easier access 369 
to eye care professionals in most European countries and a better reimbursement of medical 370 
expenses. In particular, surgical procedures for cataract surgery, and intraocular lenses, have 371 
improved over the last 20 years, increasing its availability, safety, and results in terms of visual acuity. 372 
Indeed, the proportion of visual impairment due to cataract has been reported to decrease in the last 373 
20 years, worldwide, and in particular in industrialized countries.14 Moreover, new ocular therapies 374 
have been developed in this period, including intravitreal injections of anti-vascular endothelial 375 
growth factor (VEGF) agents for exudative macular diseases (neovascular AMD, diabetic macular 376 
edema, and macular edema due to retinal vein occlusion), which were introduced in 2006.30-32 These 377 
therapies have led to major improvements in the visual prognosis of these diseases, and most 378 
probably contribute to a decrease in the overall prevalence of visual impairment.34,35 For instance, a 379 
decrease of 50 % of the incidence of blindness due to AMD has been reported in Denmark, mainly 380 
after the introduction of intravitreal therapies for AMD in 2006.33  381 
Finally, a decrease in the prevalence of eye diseases themselves may have contributed to a decrease 382 
in the prevalence of visual impairment. Indeed, it is now clear that the prevalence of diabetic 383 
retinopathy, and diabetic macular edema has decreased after year 2000, probably because of 384 
improvements in the management of diabetes (although this might be partly compensated by an 385 
increase in the prevalence of diabetes itself).34 Two American studies, and a meta-analysis in Europe, 386 
based on the E3 consortium, have also suggested that the prevalence of AMD may be lower in new 387 
generations. 35-37 388 
Similar trends have been observed in the decrease of the prevalence of other age-related disorders, 389 
in particular dementia.38-40 This suggests that recent generations are aging differently, which is 390 
probably due to multiple causes, such as changes in education, living conditions, lifestyle habits 391 
(smoking, nutrition, physical activity), and medical care. In particular, generations born after World 392 
War II, which are now entering old age, have experienced quite different living and nutritional 393 
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conditions than those born before, and may age differently. While it is usually projected that the 394 
number of disabled older individuals will dramatically grow in future years because of the aging 395 
population, these recent reports, including ours, suggest that these projections may be over-396 
pessimistic. In this changing environment, epidemiological studies need to be repeated in order to 397 
monitor the trends in the prevalence of age-related disorders and related disability. 398 
Similarly to other reports, women tended to have higher age-standardized prevalence rates of visual 399 
impairment and blindness, although this was mainly observed in the first time period (1991-2006). In 400 
the GBD meta-analysis, the prevalence of visual impairment was higher in women than in men in all 401 
world regions.25 In the NHANES study, women had higher prevalence rates of visual impairment, 402 
both in 1999-2002 (1.5% versus 1.2% for males) and in 2006-2008 (1.9% versus 1.5%), but these 403 
differences did not reach statistical significance after adjustment for age, ethnicity, poverty, 404 
education, health insurance, and diabetes. Reasons for these potential differences in visual 405 
impairment among men and women are unclear, and the differences appear to have decreased in 406 
the more recent years in Europe. 407 
The E3 consortium has provided a large data set to meta-analyze temporal trends for prevalence of 408 
visual impairment across Europe. One of the strengths is that this meta-analysis was built not only on 409 
published data, but also on unpublished data, which have not been included in previous estimates. 410 
The size of the dataset is much larger than in previous meta-analyses of European subjects, in 411 
particular for the most recent time period (2007-2012). For instance, the GBD meta-analysis included 412 
only 2 European studies conducted in this time period, both performed in Spain and totaling 1600 413 
participants, while for the same time period, the present-meta-analysis included 6 studies from 7 414 
European countries, totaling more than 36,000 participants. The estimates were also derived from 415 
raw data provided by each study following standardized procedures, in particular in the definition of 416 
the different visual endpoints.  417 
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Limitations of this consortium meta-analysis include heterogeneity between studies. Contributing 418 
studies inherently differed in study design and cohort sampling. To overcome this, we performed a 419 
random-effect rather than a fixed-effect meta-analysis, assuming no different true effect between 420 
studies. There are also differences between European countries in terms of urbanization, economy, 421 
social class, education and lifestyle, which are known to influence eye diseases. Data on these 422 
variables at an individual or study-specific level were not uniformly available, and therefore could not 423 
be included in the present study. 424 
Representativeness of the population samples is probably also heterogeneous among studies. In 425 
order to assess whether the lower prevalence rates observed in the most recent studies might be 426 
due to a lower representativeness of those studies, we performed analyses limited to the 3 most 427 
representative studies of the 2007-2012 period (Rotterdam III, Tromsø 6th, and Coimbra Eye Study). 428 
Prevalence of non-refractive visual impairment was similar in this subgroup (1.17%, 95% CI: 0.66% - 429 
1.67%) as in the main analysis for the 2007-2012 period (0.83%, 95% CI: 0.38%-1.28%), and lower 430 
than in the studies performed in 1991-2006 (2.22%, 95% CI: 1.34%-3.10%). 431 
While the E3 consortium strives to include a maximum of European research groups involved in 432 
ophthalmic epidemiology, participating studies were mostly from European high-income countries, 433 
while no studies from Central and Eastern Europe could be included, except for a small sample from 434 
Estonia. To our knowledge, only very few epidemiological studies including measurements of visual 435 
acuity have been conducted in Central and Eastern Europe. For instance, only three such studies 436 
were included in the GBD meta-analysis (including the sample from Estonia which is also included in 437 
our meta-analysis).26 However, the available data suggest that the prevalence of visual impairment 438 
and blindness may be higher in Central and Eastern Europe than in European high-income 439 
countries.26 Thus, we decided not to extrapolate our findings to those areas of Europe. 440 
Epidemiological studies conducted in these areas of Europe would be particularly informative. 441 
In addition, as shown in Table 1, the majority of participating studies collected data only in subjects 442 
aged 55 years or more. We therefore could not estimate the prevalence of visual impairment below 443 
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this age. Finally, most participating studies included only measures of best-corrected visual acuity, 444 
but not of presenting visual impairment, so it was only possible to estimate the prevalence of non-445 
refractive visual impairment. The causes of visual impairment were also generally not available. 446 
Future European epidemiological studies should strive to include measures of presenting visual 447 
acuity and to determine the causes of visual impairment, in order to give a more complete 448 
description of the epidemiology of visual impairment in Europe. In particular, uncorrected refractive 449 
errors represent a major cause of visual impairment and blindness worldwide, including in Europe 14.  450 
 451 
In conclusion, this meta-analysis supports a decrease in the prevalence and numbers of older 452 
Europeans affected by non-refractive visual impairment and blindness in the last twenty years. This 453 
decrease may be due to major improvements in eye care and/or to a generation effect on eye 454 
disease incidence. These findings underline the need for continuing epidemiological monitoring of 455 
the temporal trends of ocular health in Europe.  456 
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 556 
Figures legends: 557 
Figure 1. Prevalence (in %) of non-refractive visual impairment according to age, in studies 558 
participating to the E3 consortium (A: non-refractive visual impairment (best-corrected visual 559 
acuity<20/60); B: non-refractive visual impairment (best-corrected visual acuity<20/40); C:  560 
non-refractive blindness (best-corrected visual acuity<20/400)) 561 
 562 
Figure 2. Prevalence (in %) of non-refractive visual impairment according to age and period 563 
(non refractive visual impairment (A: non-refractive visual impairment (best-corrected visual 564 
acuity<20/60); B: non-refractive visual impairment (best-corrected visual acuity<20/40); C:  565 
non-refractive blindness (best-corrected visual acuity<20/400)) 566 
 567 
 568 
